Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$196.35 USD

196.35
1,434,682

-0.47 (-0.24%)

Updated Oct 3, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

by Zacks Equity Research

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $76.95 in the latest trading session, marking a -0.62% move from the prior day.

Top Ranked Growth Stocks to Buy for June 10th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 10th

AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

by Zacks Equity Research

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

by Zacks Equity Research

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Sanghamitra Saha headshot

Bet on 5 Top Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Top Ranked Income Stocks to Buy for June 6th

by Zacks Equity Research

Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 6th.

Pfizer to Launch Several Drugs Despite Generic Headwinds

by Zacks Equity Research

Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.

Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication

by Zacks Equity Research

Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $75.84 in the latest trading session, marking a -1.13% move from the prior day.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Vertex Selects Triple Combo Regimen for Regulatory Submission

by Zacks Equity Research

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

J&J Stock Up This Year So Far: Will the Momentum Continue?

by Zacks Equity Research

J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.

Glaxo's Shingles Vaccine Shingrix Gets Approval in China

by Zacks Equity Research

GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.

Why Is AbbVie (ABBV) Up 0.9% Since Last Earnings Report?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

by Kinjel Shah

Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

J&J's Invokana sNDA Gets Priority Review Status From FDA

by Zacks Equity Research

FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

by Zacks Equity Research

Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

Sanghamitra Saha headshot

Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Top Ranked Income Stocks to Buy for May 22nd

by Zacks Equity Research

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 22nd.

Top Ranked Income Stocks to Buy for May 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 21st.

AbbVie's Brain Cancer Candidate Fails in Phase III Study

by Zacks Equity Research

AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL

by Zacks Equity Research

Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

by Kinjel Shah

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.